Novo Nordisk stock falls after raised forecast fails to change the debate over its obesity business

Novo Nordisk raised its Ozempic obesity business forecast, but per CNBC, the market wasn't convinced—the stock fell despite the positive guidance. Wall Street doubts the company can sustain growth with Eli Lilly's competition intensifying.

Listen to this story

Hear this and more stories in a personalized audio briefing.

Open The Chonkerton